home / stock / surf / surf news

SURF News and Press, Surface Oncology Inc. From 05/20/20

Stock Information
Company Name: Surface Oncology Inc.
Stock Symbol: SURF
Market: NASDAQ
Website: surfaceoncology.com
Menu
SURF SURF Quote SURF Short SURF News SURF Articles SURF Message Board
Get SURF Alerts

News, Short Squeeze, Breakout and More Instantly...
SURF - Surface Oncology collaborates with Merck for immuno-oncology study; shares up 35%

Surface Oncology (NASDAQ: SURF ) is up  35%  premarket after entering into a clinical trial collaboration with Merck (NYSE: MRK ) to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck...
SURF - Surface Oncology Fully Utilizes its $30M At-the-Market Facility

CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology   (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 mi...

SURF - Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Me...

SURF - Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data a...
SURF - Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human,...

SURF - Surface Oncology to Present at the UBS Virtual Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the ...

SURF - Surface Oncology EPS beats by $0.54, beats on revenue

Surface Oncology (NASDAQ: SURF ): Q1 GAAP EPS of $0.74 beats by $0.54 . More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SURF - Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first qu...

SURF - Surface Oncology launches early-stage study of cancer candidate SRF388

Thinly traded nano cap Surface Oncology ( SURF +4.6% ) is up on below-average volume on the heels of its announcement that it has initiated a Phase 1 clinical trial evaluating escalating doses of interleukin-27 (IL-27) inhibitor SRF388 in patients with advanced solid tumors. More news ...

SURF - Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388

CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of i...
Previous 10 Next 10